Identifying the ubiquitin ligase complex that regulates the NF1 tumor suppressor and Ras

Cancer Discovery

Volumn 3, Issue 8, 2013, Pages 880-893

  Hollstein, Pablo E ^a,b   Cichowski, Karen ^a,b,c  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c DANA FARBER HARVARD CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CULLIN 3; KELCH REPEAT AND BTB DOMAIN CONTAINING 7; MITOGEN ACTIVATED PROTEIN KINASE; NEUROFIBROMIN; PEPTIDES AND PROTEINS; PROTEASOME; PROTEIN P53; RAS PROTEIN; TRANSCRIPTION FACTOR NRF2; UBIQUITIN PROTEIN LIGASE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME DEGRADATION; ENZYME INHIBITION; FEMALE; GLIOBLASTOMA; GROWTH INHIBITION; MASS SPECTROMETRY; MOUSE; NONHUMAN; POLYMERASE CHAIN REACTION; PROTEIN INTERACTION; RADIOIMMUNOPRECIPITATION; TUMOR XENOGRAFT; UBIQUITINATION; VIRAL GENE DELIVERY SYSTEM; WESTERN BLOTTING;

ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; CELLS, CULTURED; CULLIN PROTEINS; GENES, TUMOR SUPPRESSOR; GLIOBLASTOMA; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MAP KINASE SIGNALING SYSTEM; MICE; NEUROFIBROMIN 1; NIH 3T3 CELLS; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN STABILITY; RAS PROTEINS; TRANS-ACTIVATORS; UBIQUITIN-PROTEIN LIGASE COMPLEXES; UBIQUITINATION;

EID: 84881508723     PISSN: 21598274     EISSN: 21598290     Source Type: Journal    
DOI: 10.1158/2159-8290.CD-13-0146     Document Type: Article

References (50)

1. Bos JL. RAS oncogenes in human cancer: a review. Cancer Res 1989; 49: 4682-9.
2. Downward J. Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer 2003; 3: 11-22.
3. Pylayeva-Gupta Y, Grabocka E, Bar-Sagi D. RAS oncogenes: weaving a tumorigenic web. Nat Rev Cancer 2011; 11: 761-74.
4. Martin GA, Viskochil D, Bollag G, McCabe PC, Crosier WJ, Haubruck H, et al. The GAP-related domain of the neurofi bromatosis type 1 gene product interacts with ras p21. Cell 1990; 63: 843-9.
5. Cawthon RM, Weiss R, Xu GF, Viskochil D, Culver M, Stevens J, et al. A major segment of the neurofi bromatosis type 1 gene: cDNA sequence, genomic structure, and point mutations. Cell 1990; 62: 193-201.
6. Min J, Zaslavsky A, Fedele G, McLaughlin SK, Reczek EE, De Raedt T, et al. An oncogene-tumor suppressor cascade drives metastatic prostate cancer by coordinately activating Ras and nuclear factor-kappaB. Nat Med 2010; 16: 286-94.
7. Bernards A. GAPs galore! A survey of putative Ras superfamily GTPase activating proteins in man and Drosophila. Biochim Biophys Acta 2003; 1603: 47-82.
8. Riccardi VM. Neurofi bromatosis: phenotype, natural history, and pathogenesis. 2nd ed. Baltimore and London: The Johns Hopkins University Press; 1992.
9. Cancer Genome Atlas Research Network. Comprehensive genomic characterization defi nes human glioblastoma genes and core pathways. Nature 2008; 455: 1061-8.
10. Parsons DW, Jones S, Zhang X, Lin JC-H, Leary RJ, Angenendt P, et al. An integrated genomic analysis of human glioblastoma multiforme. Science 2008; 321: 1807-12.
11. McGillicuddy LT, Fromm JA, Hollstein PE, Kubek S, Beroukhim R, De Raedt T, et al. Proteasomal and genetic inactivation of the NF1 tumor suppressor in gliomagenesis. Cancer Cell 2009; 16: 44-54.
12. Ding L, Getz G, Wheeler DA, Mardis ER, McLellan MD, Cibulskis K, et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature 2008; 455: 1069-75.
13. The I, Murthy AE, Hannigan GE, Jacoby LB, Menon AG, Gusella JF, et al. Neurofi bromatosis type 1 gene mutations in neuroblastoma. Nat Genet 1993; 3: 62-6.
14. Hölzel M, Huang S, Koster J, Ora I, Lakeman A, Caron H, et al. NF1 is a tumor suppressor in neuroblastoma that determines retinoic acid response and disease outcome. Cell 2010; 142: 218-29.
15. Maertens O, Johnson B, Hollstein P, Frederick DT, Cooper ZA, Messaien L, et al. Elucidating distinct roles for NF1 in melanomagenesis. Cancer Discov 2013; 3: 338-49.
16. Whittaker SR, Theurillat J-P, Van Allen E, Wagle N, Hsiao J, Cowley GS, et al. A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition. Cancer Discov 2013; 3: 350-62.
17. Andersen LB, Fountain JW, Gutmann DH, Tarlé SA, Glover TW, Dracopoli NC, et al. Mutations in the neurofibromatosis 1 gene in sporadic malignant melanoma cell lines. Nat Genet 1993; 3: 118-21.
18. Honda R, Tanaka H, Yasuda H. Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett 1997; 420: 25-7.
19. Sherr CJ, Weber JD. The ARF/p53 pathway. Curr Opin Genet Dev 2000; 10: 94-9.
20. Bloom J, Pagano M. Deregulated degradation of the cdk inhibitor p27 and malignant transformation. Semin Cancer Biol 2003; 13: 41-7.
21. Wang X, Trotman LC, Koppie T, Alimonti A, Chen Z, Gao Z, et al. NEDD4-1 is a proto-oncogenic ubiquitin ligase for PTEN. Cell 2007; 128: 129-39.
22. Cheok CF, Verma CS, Baselga J, Lane DP. Translating p53 into the clinic. Nat Rev Clin Oncol 2011; 8: 25-37.
23. Cichowski K, Santiago S, Jardim M, Johnson BW, Jacks T. Dynamic regulation of the Ras pathway via proteolysis of the NF1 tumor suppressor. Genes Dev 2003; 17: 449-54.
24. Petroski MD, Deshaies RJ. Function and regulation of cullin-RING ubiquitin ligases. Nat Rev Mol Cell Biol 2005; 6: 9-20.
25. Willems AR, Schwab M, Tyers M. A hitchhiker's guide to the cullin ubiquitin ligases: SCF and its kin. Biochim Biophys Acta 2004; 1695: 133-70.
26. Cardozo T, Pagano M. The SCF ubiquitin ligase: insights into a molecular machine. Nat Rev Mol Cell Biol 2004; 5: 739-51.
27. Furukawa M, He YJ, Borchers C, Xiong Y. Targeting of protein ubiquitination by BTB-Cullin 3-Roc1 ubiquitin ligases. Nat Cell Biol 2003; 5: 1001-7.
28. Cullinan SB, Gordan JD, Jin J, Harper JW, Diehl JA. The Keap1-BTB protein is an adaptor that bridges Nrf2 to a Cul3-based E3 ligase: oxidative stress sensing by a Cul3-Keap1 ligase. Mol Cell Biol 2004; 24: 8477-86.
29. Pickart CM. Back to the future with ubiquitin. Cell 2004; 116: 181-90.
30. Lowy DR, Willumsen BM. Function and regulation of ras. Annu Rev Biochem 1993; 62: 851-91.
31. McEvoy JD, Kossatz U, Malek N, Singer JD. Constitutive turnover of cyclin E by Cul3 maintains quiescence. Mol Cell Biol 2007; 27: 3651-66.
32. Xu L, Wei Y, Reboul J, Vaglio P, Shin T-H, Vidal M, e t al. BTB proteins are substrate-specifi c adaptors in an SCF-like modular ubiquitin ligase containing CUL-3. Nature 2003; 425: 316-21.
33. Beroukhim R, Getz G, Nghiemphu L, Barretina J, Hsueh T, Linhart D, et al. Assessing the signifi cance of chromosomal aberrations in cancer: methodology and application to glioma. Proc Natl Acad Sci U S A 2007; 104: 20007-12.
34. Pintard L, Willis JH, Willems A, Johnson J-LF, Srayko M, Kurz T, et al. The BTB protein MEL-26 is a substrate-specifi c adaptor of the CUL-3 ubiquitin-ligase. Nature 2003; 425: 311-6.
35. Geyer R, Wee S, Anderson S, Yates J, Wolf DA. BTB/POZ domain proteins are putative substrate adaptors for cullin 3 ubiquitin ligases. Mol Cell 2003; 12: 783-90.
36. Stogios PJ, Downs GS, Jauhal JJS, Nandra SK, Privé GG. Sequence and structural analysis of BTB domain proteins. Genome Biol 2005; 6: R82.
37. Yaron A, Hatzubai A, Davis M, Lavon I, Amit S, Manning AM, et al. Identifi cation of the receptor component of the IkappaBalphaubiquitin ligase. Nature 1998; 396: 590-4.
38. Angers S, Li T, Yi X, MacCoss MJ, Moon RT, Zheng N. Molecular architecture and assembly of the DDB1-CUL4A ubiquitin ligase machinery. Nature 2006; 443: 590-3.
39. Angers S, Thorpe CJ, Biechele TL, Goldenberg SJ, Zheng N, MacCoss MJ, et al. The KLHL12-Cullin-3 ubiquitin ligase negatively regulates the Wnt-beta-catenin pathway by targeting Dishevelled for degradation. Nat Cell Biol 2006; 8: 348-57.
40. Maerki S, Olma MH, Staubli T, Steigemann P, Gerlich DW, Quadroni M, et al. The Cul3-KLHL21 E3 ubiquitin ligase targets aurora B to midzone microtubules in anaphase and is required for cytokinesis. J Cell Biol 2009; 187: 791-800.
41. Marshall CJ. Specifi city of receptor tyrosine kinase signaling: transient versus sustained extracellular signal-regulated kinase activation. Cell 1995; 80: 179-85.
42. Soucy TA, Smith PG, Milhollen MA, Berger AJ, Gavin JM, Adhikari S, et al. An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer. Nature 2009; 458: 732-6.
43. Soucy TA, Dick LR, Smith PG, Milhollen MA, Brownell JE. The NEDD8 conjugation pathway and its relevance in cancer biology and therapy. Genes Cancer 2010; 1: 708-16.
44. Chen Q, Xie W, Kuhn DJ, Voorhees PM, Lopez-Girona A, Mendy D, et al. Targeting the p27 E3 ligase SCF(Skp2) results in p27-and Skp2-mediated cell-cycle arrest and activation of autophagy. Blood 2008; 111: 4690-9.
45. Orlicky S, Tang X, Neduva V, Elowe N, Brown ED, Sicheri F, et al. An allosteric inhibitor of substrate recognition by the SCF(Cdc4) ubiquitin ligase. Nat Biotechnol 2010; 28: 733-7.
46. Aghajan M, Jonai N, Flick K, Fu F, Luo M, Cai X, et al. Chemical genetics screen for enhancers of rapamycin identifi es a specifi c inhibitor of an SCF family E3 ubiquitin ligase. Nat Biotechnol 2010; 28: 738-42.
47. Vassilev LT. MDM2 inhibitors for cancer therapy. Trends Mol Med 2007; 13: 23-31.
48. Brugarolas J, Bronson RT, Jacks T. p21 is a critical CDK2 regulator essential for proliferation control in Rb-defi cient cells. J Cell Biol 1998; 141: 503-14.
49. Campeau E, Ruhl VE, Rodier F, Smith CL, Rahmberg BL, Fuss JO, et al. A versatile viral system for expression and depletion of proteins in mammalian cells. PLoS ONE 2009; 4: e6529.
50. Johannessen CM, Reczek EE, James MF, Brems H, Legius E, Cichowski K. The NF1 tumor suppressor critically regulates TSC2 and mTOR. Proc Natl Acad Sci U S A 2005; 102: 8573-8.